Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 9:2022:3129389.
doi: 10.1155/2022/3129389. eCollection 2022.

Tacrolimus Concentration Is Effectively Predicted Using Combined Clinical and Genetic Factors in the Perioperative Period of Kidney Transplantation and Associated with Acute Rejection

Fang Cheng  1   2 , Qiang Li  1   2 , Zheng Cui  1   2 , Zhendi Wang  3 , Fang Zeng  1   2 , Yu Zhang  1   2
Affiliations

Tacrolimus Concentration Is Effectively Predicted Using Combined Clinical and Genetic Factors in the Perioperative Period of Kidney Transplantation and Associated with Acute Rejection

Fang Cheng et al. J Immunol Res. .

Abstract

Background: Tacrolimus has unpredictable pharmacokinetic (PK) characteristics, which are partially attributed to CYP3A5 polymorphism. The potential effects of clinical factors in the postoperative period of transplantation on tacrolimus PK and those of early tacrolimus PK variability on clinical outcomes are yet to be clarified.

Methods: We examined the genetic and clinical factors affecting early tacrolimus PK variability in 256 kidney transplant recipients. The relationships among tacrolimus exposure, graft function delay (DGF), and acute rejection (AR) were further explored. Findings. The CYP3A5 genotype were strongly associated with tacrolimus concentration/dose ratio (C 0/D). Additionally, ABCB1 (rs1045642 and rs2032582) and ABCC2 (rs3740066) were found to have potential independent effects on early tacrolimus C 0/D in multivariate analysis. Red blood counts and albumin level were the most significant clinical factors associated with tacrolimus C 0/D. Wuzhi capsule also exerted an effect on tacrolimus PK. A model combined with pharmacogenetic and clinical factors explained 43.4% tacrolimus PK variability compared with 16.3% on the basis of CYP3A5 genotype only. Notably, increasing tacrolimus concentrations in the early postoperative stage were associated with AR, but not DGF.

Conclusions: Combined analysis of genotype and specific clinical factors is important for the formulation of precise tacrolimus dose regimens in the early stage after kidney transplantation.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Individual trends of tacrolimus concentration.
Figure 2
Figure 2
Effect of the CYP3A5 genotype on tacrolimus PK variability.
Figure 3
Figure 3
Associations among early tacrolimus concentration, delayed graft function (DGF), and acute rejection (AR). The average tacrolimus concentration was classified as follows: <8 ng/mL; 8–12 ng/mL; and >12 ng/mL. (a) Incidence rate of DGF by tacrolimus concentration. (b) Incidence rate of AR by tacrolimus concentration. ∗∗p < 0.01 for tacrolimus concentration < 8 ng/mL VS. 8 ng/mL < tacrolimus concentration < 12 ng/mL. #p < 0.05 for tacrolimus concentration < 8 ng/mLVS. tacrolimus concentration > 12 ng/mL.
See this image and copyright information in PMC

References

    1. First M. R. Tacrolimus based immunosuppression. Journal of Nephrology . 2004;17(Suppl 8):S25–S31. - PubMed
    1. Schumacher L., Leino A. D., Park J. M. Tacrolimus intrapatient variability in solid organ transplantation: a multiorgan perspective. Pharmacotherapy . 2021;41(1):103–118. doi: 10.1002/phar.2480. - DOI - PubMed
    1. Degraeve A. L., Moudio S., Haufroid V., et al. Predictors of tacrolimus pharmacokinetic variability: current evidences and future perspectives. Expert Opinion on Drug Metabolism & Toxicology . 2020;16(9):769–782. doi: 10.1080/17425255.2020.1803277. - DOI - PubMed
    1. Tron C., Lemaitre F., Verstuyft C., Petitcollin A., Verdier M. C., Bellissant E. Pharmacogenetics of membrane transporters of tacrolimus in solid organ transplantation. Clinical Pharmacokinetics . 2019;58(5):593–613. doi: 10.1007/s40262-018-0717-7. - DOI - PubMed
    1. Hashimoto Y., Sasa H., Shimomura M., Inui K. Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. Pharmaceutical Research . 1998;15(10):1609–1613. doi: 10.1023/A:1011967519752. - DOI - PubMed